Originally published In Press as doi:10.1074/jbc.R700001200 on February 28, 2007
J. Biol. Chem., Vol. 282, Issue 18, 13141-13145, May 4, 2007
Minireview
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation*
Shwu-Yuan Wu and
Cheng-Ming Chiang1
From the
Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106
 |
ABSTRACT
|
|---|
Brd4 is a double bromodomain-containing protein that binds preferentially to acetylated chromatin. It belongs to the BET (bromodomains and extraterminal) family that includes mammalian Brd2, Brd3, Brd4, Brdt, Drosophila Fsh, yeast Bdf1, Bdf2, and corresponding homologues in other species. Brd4 is essential for cellular growth and has been implicated in cell cycle control, DNA replication, and gene rearrangement found in t(15;19)-associated carcinomas. Recently, Brd4 has been found in several transcription complexes, including the general cofactor Mediator and the P-TEFb elongation factor, and is capable of stimulating HIV-1 transcription in a Tat-independent manner. In addition, Brd4 is used as a cellular adaptor by some animal and human papillomaviruses (HPV) for anchoring viral genomes to mitotic chromosomes. This tethering, mediated by Brd4 interaction with virus-encoded E2 protein, facilitates viral genome segregation during mitosis. Interestingly, Brd4 is also identified in a transcriptional silencing complex assembled by HPV E2 and turns out to be the long sought cellular corepressor that inhibits the expression of HPV-encoded E6 and E7 oncoproteins that antagonize p53 and pRB tumor suppressor activity, respectively. The dual role of Brd4 in gene activation and repression illustrates how a dynamic chromatin-binding adaptor is able to recruit distinct transcriptional regulators to modulate promoter activity through cell cycle progression.
|
Brd4 and BET Family Proteins
|
|---|
Bromodomain-containing protein 4 (Brd4)2 is a member of the BET family that in yeast and animals contains two tandem bromodomains (BDI and BDII) and an extraterminal (ET) domain (1). The bromodomain is a conserved region of 
110 amino acids that structurally forms 4 
-helices (z, A, B, and C) and 2 loops, linking z and A (ZA loop) and B and C (BC loop), capable of binding acetyl-lysine residues in histones and many other proteins (2). In humans, four BET proteins (Brd2, Brd3, Brd4, and Brdt) exhibit similar gene arrangements, domain organizations, and some functional properties. Brd2, formerly named RING3 (really interesting new gene 3) or Fshrg1 (female sterile homeotic related gene 1), is a nuclear serine/threonine kinase possessing chromatin binding activity with preference for acetylated lysine 12 on histone H4 and transcription activity via its association with transcriptional regulators such as E2F1 (3, 4). Brd3 (also called ORFX or Fshrg2) and Brdt (for bromodomain, testis-specific) are less well characterized although mouse Brdt has been reported to induce global chromatin reorganization in an acetylation-dependent manner (5). Brd4, originally named MCAP (mitotic chromosome-associated protein; Ref. 6) but also called Fshrg4 or Hunk1, is a chromatin binding factor with preference for acetylated Lys-14 on histone H3 and Lys-5/12 on H4 (7). Except for Brdt, which is expressed specifically in testis and ovary, Brd2, Brd3, and Brd4 are widely distributed (8, 9). Interestingly, the chromosomal locations of these Brd genes are adjacent to the four Notch genes found in the human genome with Brd2 and Notch4 on chromosome 6, Brd3 and Notch1 on chromosome 9, Brd4 and Notch3 on chromosome 19, and Brdt and Notch2 on chromosome 1 (10, 11), indicating a likely functional relationship between human Brd and Notch gene families.
The domain organization of mammalian Brd proteins is conserved and extends to homologues in other species, including Drosophila Fsh and Saccharomyces cerevisiae Bdf1 and Bdf2 proteins (Fig. 1A). Although BDI, BDII, and the ET domain are characteristic of the BET family proteins, other domains, such as motifs B and SEED (Ser/Glu/Asp-rich region), are also highly conserved (9). The C-terminal motif (CTM) (12) and motif A (9), however, are not present in every protein. The sequence feature and alignment of each domain across different species are presented in supplemental Figs. 1 and 2. Other than the gene paralogues, many of the BET proteins exist in two (i.e. long and short) isoforms generated by alternatively spliced transcripts differing at their 3' ends (Fig. 1B). The long form of human and mouse Brd4 is often the only isoform detected (6, 8) and accounts for the majority of the biological activity. The function of the short form (also known as Hunk1 in humans), if expressed (13), remains undefined. Interestingly, a fusion protein, containing the N-terminal 719 amino acids of human Brd4 linked to the nearly complete Nut (nuclear protein in testis) protein (spanning amino acids 6–1132, missing only the first 5 residues) caused by t(15:19)(q13,p13.1) chromosomal translocation, has been reported in some epithelial carcinomas (13).
|
Protein-Protein Interactions Mediated by Bromodomains, ET, and CTM
|
|---|
BDI and BDII exhibit less homology (44% identity) to each other within the same protein compared with their homologous domains (>75% identity) in other BET proteins (14). However, amino acid residues critical for binding acetyl-lysine in BDI and BDII are highly conserved. Similar to mammalian Brd4, yeast Bdf1 (but not Bdf2) binds preferentially to acetylated H3 and H4 (15) and, in addition, plays an antisilencing role by preventing the silent information regulator (Sir)-mediated spreading of heterochromatin via competition with Sir2 binding to acetylated H4 at heterochromatin-euchromatin boundaries (16). From structure-based mutagenesis studies conducted with human Brd2 (4) and yeast Bdf1 (15, 16), the conserved amino acid residues in human Brd4 bromodomains likely important for binding acetyl-lysine include: Pro-86, Val-87, Tyr-97, Pro-104, and Met-105 in the ZA loop of BDI; Tyr-139, Asn-140, and Ile-146 at the BC loop-helix junctions of BDI; Pro-379, Val-380, Tyr-390, Pro-397, and Met-398 in the ZA loop of BDII; and Tyr-432, Asn-433, and Val-439 at the BC loop-helix junctions of BDII (Fig. 2A). Interestingly, the crystal structure of human Brd2 BDI reveals formation of a BDI homodimer containing two acetyl-lysine-binding pockets and a negatively charged secondary binding pocket formed at the dimer interface (14). The existence of a secondary binding pocket, formed by homodimeric (e.g. BDI-BDI) or heterodimeric bromodomains (e.g. BDI-BDII), likely helps determine the binding specificity between bromodomains and different acetyl-lysine residues. The secondary binding pocket may also provide an independent surface for acetyl-lysine-independent bromodomain-histone interactions (15) and underlie the observation that deletion of one bromodomain in a BET protein fails to eliminate its chromatin binding and transcriptional activity (4, 17). Based on the characterized residues in human Brd2 (supplemental Fig. 1), the amino acids in human Brd4 potentially involved in homodimeric interactions include but are not limited to Gln-62, Met-126, Gln-127, Tyr-137, Ile-138, Glu-154, Leu-158, Ile-161, and Gln-166 in BDI, and Gln-353, Gly-419, Ala-420, Tyr-430, Lys-431, Gln-447, Glu-451, Phe-454, and Asp-459 in BDII (see green letters in Fig. 2A).
View larger version (34K):
[in this window]
[in a new window]
|
FIGURE 1.
Domain organization of Brd4 family proteins. A, human (h), Drosophila (d), and yeast (y) BET proteins. Numbers indicate the amino acid boundaries of each domain or the corresponding amino acid residues of individual proteins. Alignment of amino acid sequences is conducted with ClustalW software based on published information (1, 9, 12, 14) using the following accession numbers retrieved from GenBank databases: hBrd2, NM_005104; hBrd3, NM_007371; hBrd4, NM_058243; hBrdt, NM_207189; dFsh, M23221; yBdf1, NP_013503 (derived from NC_001144); and yBdf2, Z74119. Motifs A and B are two conserved regions recently identified by sequence alignments (9), whereas SEED represents a conserved motif containing polyserine residues interspersed with glutamic (E) and aspartic (D) acid residues (1). CTM is a conserved C-terminal motif of 38 amino acid residues found in mammalian Brd4, Brdt, and Drosophila Fsh (see supplemental Fig. 2). B, protein isoforms of mouse and human Brd4 proteins. The short forms of mouse and human Brd4 have the same N-terminal amino acid residues (720 for mouse and 719 for human) as found in their long forms but differ in the last three amino acids (GPA), which are encoded by a different exon. Human Brd4-Nut has 1846 amino acid residues linking amino acids 1–719 of hBrd4 to amino acids 6–1132 of Nut. NLS (nuclear localization signal) depicts the corresponding region in mouse Brd4 (amino acids 146–350) characterized to be essential for its nuclear localization (20). Accession numbers for additional coding sequences: mBrd4, NM_020508; mouse Brd4 short, NM_198094; human Brd4 short, NM_014299; and human Nut, NM_175741.
|
|
Besides binding acetylated chromatin, BDI and BDII also interact with nonhistone proteins to regulate transcription, DNA replication, cell cycle progression, and other cellular activities. A BDII-containing region in mouse Brd4 has been shown to interact with several cellular and viral proteins, including the cyclin T1 component of human positive transcription elongation factor b (P-TEFb) (18, 19), the RFC-140 subunit of human replication factor C (20), signal-induced proliferation-associated protein 1 (SPA-1) (21), and HPV-11 E2 protein (17) (Fig. 2B). Whether these interactions are truly mediated by BDII or amino acids further downstream remains to be defined. In the cases of cyclin T1 and HPV-11 E2, a second interaction region separate from the BDII-containing region of Brd4 has also been identified. The ET domain seems to serve as a protein-protein interaction module between human Brd4 and Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen 1 (LANA-1) (22, 23) and between yeast Bdf1 and the TAF7 subunit of the general transcription factor TFIID (24). A region containing the SEED motif downstream of the ET domain in human Brd2 is critical for interaction with E2F1 and E2F2 and thus may underline the role of Brd2 in E2F-dependent transcription and cell cycle control (3). The CTM encompassed in a larger C-terminal domain of mouse and human Brd4 has been shown to interact with E2 encoded by different types of papillomaviruses and appears to be important for viral genome segregation (see below). An alanine substitution of Phe-1349 or Asp-1352 in the CTM of human Brd4 abolishes Brd4 interaction with HPV-16 E2 (12). These two residues are also conserved in the CTM of mouse Brd4, human Brdt, and Drosophila Fsh (see Fig. 1 and supplemental Fig. 2).
|
Role of Brd4 in Cell Cycle Progression
|
|---|
Brd4 is a ubiquitously expressed protein of 200 kDa first identified in mouse as MCAP because of its chromosome binding activity (6). As described for yeast Bdf1 (25) and human Brd2 (4), association of Brd4 with chromatin persists throughout the cell cycle (7). A unique feature of the BET proteins lies in their ability to associate with mitotic chromosomes, unlike other bromodomain-containing proteins, such as p300, CBP, GCN5, and the hBrm/hSNF2 and hBrg1/hSNF2
subunits of human SWI/SNF chromatin remodeling complex (26), which are typically displaced from condensed chromosomes during mitosis. Inhibition of mouse Brd4 function by injecting anti-Brd4 antibodies into proliferating cells leads to G2/M arrest (6), presumably because of an imbalance between Brd4 and SPA-1 activity needed in G2 for cell division (21). In contrast, overexpression of Brd4 in cultured cells results in G1/S arrest (20). This may be caused by Brd4-mediated repression of replication factor C function during DNA replication (20). Not surprisingly, knockout of Brd4 in mice is embryonic lethal (11), and severe knockdown of Brd4 in cultured human cells significantly reduces cell growth (17). Because Brd4 haploinsufficiency in Brd4+/– cells is linked to reduced levels of acetylated Lys-14 on H3 and acetylated Lys-12 on H4 as well as impaired reloading of Brd4 onto chromosomes following removal of anti-microtubule drugs that disrupt Brd4 binding to chromosomes (27), it seems that Brd4 also plays an important role in maintaining the global acetylation state of chromatin in the cell. In this aspect, it will be of interest to examine whether t(15;19) chromosomal translocation leads to Brd4 haploinsufficiency, which may correlate with increased chromosomal missegregation observed in Brd4+/– cells (27) and whether ectopical expression of Brd4-Nut that also causes G1/S arrest (28) can substitute for (or antagonize) some function of Brd4.
|
Brd4 Found in Selective Forms of Mediator Complexes
|
|---|
An indication that Brd4 is directly implicated in transcriptional control is provided by the analysis of a mouse Mediator complex that contains an uncharacterized subunit with sequence homology to human Brd2/RING3 (29). Comparison of the RING3-like peptide sequences with known Brd2 family proteins suggests that the RING3-like protein is likely to be mouse Brd4 (11). This issue is now resolved by experimentation illustrating that human Brd4, rather than Brd2, is the RING3-like protein found in human Mediator complexes purified from the P11 0.5 M KCl fraction (P.5) (30) prepared from a HeLa-derived cell line expressing the FLAG-tagged Med7 (f:Med7) subunit of human Mediator (supplemental Fig. 3, lane 2). Because Mediator-P.5 contains at least two forms of Mediator differing in the presence or absence of a Cdk8-containing module (30), we separated these two forms by immunodepletion of Cdk8 (30) and found that the amount of Brd4 associated with Mediator-P.5 remains the same (supplemental Fig. 3, lane 2 versus lane 3). Interestingly, Brd4 was not detected in human Mediator isolated from the P11 0.85 M KCl fraction (P.85) (30) and in human TFIID (31) (supplemental Fig. 3, lanes 4 and 5). This finding demonstrates that Brd4, rather than Brd2, is indeed associated with Mediator, but only selective forms of Mediator complexes contain Brd4, most likely through its interaction with a subunit of Mediator not present in the Cdk8 module. It should be noted that yeast Bdf1, considered to be the counterpart of the C-terminal region of human and Drosophila TAF1, is only found in some populations of yeast TFIID (24, 32). Perhaps a dynamic association of Brd4 with Mediator allows it to interact with different protein complexes in responding to the specific need of gene activity in a cell.
|
Brd4 Present in Distinct Forms of P-TEFb Complexes
|
|---|
A proteomic analysis of human proteins associated with mouse Brd4 identified cyclin T1, Cdk9, and several components of human Mediator in the Brd4 complexes (18). Interestingly, Brd4 is only found in the P-TEFb complex containing cyclin T1 and Cdk9 without the inhibitory protein HEXIM1 and 7SK small nuclear RNA (19). It is estimated that the active form (cyclin T-Cdk9-Brd4) and the repressive form (cyclin T-Cdk9-HEXIM1–7SK RNA) of P-TEFb each account for 50% of P-TEFb in the cell (19). The association of Brd4 in active P-TEFb suggests that Brd4 is involved in transcription by RNA polymerase II (pol II). Indeed, transcription of some cellular genes, such as c-myc and c-jun, and the HIV-1 promoter, is enhanced by Brd4, which also stimulates Cdk9-mediated phosphorylation of serine 2 at the C-terminal domain (CTD) of pol II (18). Recruitment of Brd4 and Cdk9 to an integrated HIV-1 promoter is significantly increased by treatment of cultured cells with a histone deacetylase inhibitor (18). These experiments illustrate a positive role of Brd4 in pol II-dependent transcription through enhanced recruitment of the active P-TEFb complex to acetylated chromatin in the promoter region. However, Brd4-mediated enhancement of pol II-dependent transcription can also occur in vitro with nucleosome-free DNA templates containing the HIV-1 promoter with or without the Tat-responsive region (19). This Tat-independent stimulation requires Brd4, as transcription of the HIV-1 promoter in Cdk9-depleted nuclear extracts could only be restored by adding back wild-type Cdk9 but not the Cdk9-S175D mutant that retains CTD kinase activity but fails to interact with Brd4 (19). Moreover, a Mediator component (TRAP220) could only be found in pull-down complexes containing wild-type Cdk9 but not the S175D mutant, suggesting P-TEFb interaction with Mediator is Brd4-dependent (19). It is likely that Brd4 binding to acetylated chromatin, facilitated by a Brd4-interacting DNA-binding protein (see below), helps recruit Mediator to the promoter region (Fig. 3A). Following initiation of transcription and serine 5 phosphorylation of the pol II CTD by TFIIH and presumably Mediator as well, Brd4-associated Mediator then recruits core P-TEFb (cyclin T1-Cdk9) when pol II is stalled at the downstream promoter region during promoter clearance and enhances cyclin T1-mediated serine 2 phosphorylation of the pol II CTD. Clearly, Brd4 plays a multiple role in stimulating pol II-dependent transcription at both chromatin and DNA levels.
View larger version (37K):
[in this window]
[in a new window]
|
FIGURE 3.
Involvement of Brd4 in gene activation and repression. A, model for Brd4-mediated activation of the HIV-1 promoter. Brd4 binding to acetylated (Ac) histone tails, which is enhanced by a sequence-specific DNA-binding protein (indicated by an unnamed oval), recruits Mediator, individually or together with pol II, to the promoter region. Following initiation, Brd4 enhances P-TEFb (cyclin T1/Cdk9) recruitment to stalled pol II and stimulates phosphorylation of the pol II CTD by P-TEFb, thereby increasing pol II-dependent transcription of the HIV-1 promoter. B, model for Brd4-mediated repression of the HPV promoter. Dynamic binding (i.e. fast "on" and "off") of Brd4 to acetylated (Ac) chromatin via its bromodomains (BD) is stabilized by CTM-mediated recruitment of HPV E2 to the promoter region. E2 then inhibits HPV transcription by preventing preinitiation complex assembly.
|
|
|
Brd4 Found in an HPV Transcriptional Silencing Complex
|
|---|
HPV E2 is a sequence-specific DNA-binding protein involved in viral DNA replication, transcription, genome maintenance, and segregation. Intriguingly, Brd4 is identified in a protein complex containing E2 encoded by either bovine papillomavirus type 1 (BPV-1) (33) or HPV-11 (17). As a transcriptional regulator, HPV E2 mainly acts as a repressor to inhibit viral gene expression, including E6 and E7 oncoproteins that antagonize p53 and pRB tumor suppressor activity (17). The identification of Brd4 as a component in a dominant form of E2 complexes indicates that Brd4 may be the long sought cellular cofactor for HPV E2 repressor function. Indeed, recombinant Brd4 and E2 are both necessary and sufficient to replace the purified E2 repressor complex in inhibiting AP-1-dependent HPV chromatin transcription in an E2-binding site-specific manner, as illustrated by reconstituted chromatin transcription experiments in which the in vitro assembled HPV chromatin faithfully recapitulates the positioning of nucleosomes typically observed in vivo (17). The requirement of Brd4 in E2-mediated repression of HPV transcription is further demonstrated in living cells by both transient and stable knockdown of Brd4. Apparently, chromatin-bound Brd4 recruits E2 that in turn prevents the recruitment of TFIID and pol II to the HPV promoter. Surprisingly, the levels of acetylated H3 and H4 in the E6 promoter region are not reduced, suggesting that acetylated chromatin is probably necessary for binding of Brd4 and thereby for E2-mediated repression (17). Interestingly, enhanced binding of Brd4 to acetylated chromatin following sodium butyrate (a histone deacetylase inhibitor) treatment of HeLa cells that express HPV-11 E2 only occurs at the region where an E2-binding site is situated. As expected, the recruitment of E2 to its cognate binding site is also augmented, paralleling with enhanced Brd4 recruitment (17). This finding suggests that acetylated chromatin alone is not sufficient to stabilize Brd4 binding to chromatin and that a synergistic binding between Brd4 and a sequence-specific DNA-binding protein that interacts with Brd4, such as E2, is necessary for mutual enhancement of binding to acetylated chromatin (Fig. 3B). This notion is consistent with a rapid "on" and "off" mode of Brd4 binding to acetylated chromatin in living cells (7, 34). It is important to mention that although Brd4 is efficiently recruited to HPV chromatin, it is not universally found in every gene. Furthermore, at least one bromodomain of Brd4 is required for chromatin targeting and for E2 recruitment to acetylated chromatin (17). Once E2 accesses its binding sites adjacent to the TATA box, it blocks TFIID binding and further prevents TFIIF-escorted pol II entry to the promoter region (35, 36). It is likely that Brd4 also modulates E2 interactions with DNA and with general cofactors Mediator, TFIID, and positive cofactor 4 (PC4), as well as components of the general transcription machinery (37) to fine-tune the efficiency of preinitiation complex assembly, correlating with its involvement in gene activation and repression.
|
Brd4 Is an Authentic Transcriptional Cofactor
|
|---|
The dual role of Brd4 in gene activation (Fig. 3A) and repression (Fig. 3B) classifies it as an authentic transcriptional cofactor, similar to the regulatory properties exemplified by general cofactors Mediator, TFIID, USA-derived components (38), and p300 (39). A coactivating role of Brd4 in E2-mediated activation of heterologous promoters containing multimerized E2-binding sites has also been reported (40–42). It will be interesting to see whether E2-mediated activation also requires Mediator and P-TEFb, as seen with the HIV-1 promoter. Equally important is to define chromatin-independent properties of Brd4 in transcriptional activation and repression.
|
Brd4 in Viral Genome Segregation and Beyond
|
|---|
Because E2 is also implicated in viral genome maintenance and segregation (12, 33, 43–45), it is intriguing to find that Brd4 is able to bridge E2-bound BPV-1 and HPV genomes onto mitotic chromosomes and thus facilitate viral genome segregation during mitosis. Based on the defined interaction domains, the structure of the N-terminal 201 amino acids of HPV-16 E2 in complex with the C-terminal 20 amino acids of human Brd4 has been solved by x-ray crystallography at 1.59-angstrom resolution (12). Two amino acids in the human Brd4 peptide (Phe-1349 and Asp-1352) shown to be critical for E2 interaction are conserved among CTM-containing BET proteins (see Fig. 1A). This conservation suggests that CTM-binding cellular proteins may exist in the cell to modulate Brd4 activity, a caveat potentially complicating the interpretation of data relying on the use of CTM-containing domains as dominant negative mutants for functional studies. Although Brd4 appears to be the cellular adaptor for some animal and HPV types, E2 encoded by other HPVs does not colocalize with Brd4 in mitotic chromosomes (42–44). This discrepancy, even for the same type of viral genomes mapped in different laboratories, raises the concern of whether Brd4 is the only cellular adaptor for tethering viral genomes to mitotic chromosomes or other mitotic apparatus, such as spindles (46). Indeed, another E2-interacting human protein, ChlR1 (chromosome loss-related protein 1), has recently been shown to be the tethering factor for BPV-1 genomes (47). Interestingly, HPV-11 E2 also associates with SMC5 (structural maintenance of chromosome 5) and SMC6 (17), which in turn interact with cohesin components SMC1 and SMC3 (48) that also complex with ChlR1 (49). Accordingly, E2 may interact sequentially or simultaneously with multiple chromosome-binding proteins to facilitate viral genome maintenance, tethering, and segregation in latently infected cells. Whether each of these E2-interacting chromatin adaptors also plays a role in HPV transcription, as demonstrated for Brd4, will be of great interest for future investigations. Undoubtedly, Brd4 has emerged as a central player in transcription, DNA replication, cell cycle control, oncogenesis, and viral genome segregation and is clearly an excellent working model for many chromatin adaptors.
|
FOOTNOTES
|
|---|
* This minireview will be reprinted in the 2007 Minireview Compendium, which will be available in January, 2008. The research conducted in the Chiang laboratory is currently sponsored by NIH Grants CA103867 and CA124760. 
The on-line version of this article (available at http://www.jbc.org) contains supplemental figures 1–3.
1 To whom correspondence should be addressed. E-mail: cmc23{at}cwru.edu.
2 The abbreviations used are: Brd4, bromodomain-containing protein 4; BDI, bromodomain I; BDII, bromodomain II; ET, extraterminal domain; SEED, Ser/Glu/Asp-rich region; CTM, C-terminal motif; CTD, C-terminal domain; P-TEFb, positive elongation factor b; HPV, human papillomavirus; Mediator-P.5, Mediator isolated from the P11 0.5 M KCl fraction; pol II, RNA polymerase II; BPV, bovine papillomavirus.
|
ACKNOWLEDGMENTS
|
|---|
We are grateful to Alison S. Chiang for art illustration and Steve Buratowski, David Samols, and A-Young Lee for comments on the manuscript.
|
REFERENCES
|
|---|
- Florence, B., and Faller, D. V. (2001) Front. Biosci. 6, D1008–1018[Medline]
[Order article via Infotrieve]
- Zeng, L., and Zhou, M.-M. (2002) FEBS Lett. 513, 124–128[CrossRef][Medline]
[Order article via Infotrieve]
- Denis, G. V., Vaziri, C., Guo, N., and Faller, D. V. (2000) Cell Growth & Differ. 11, 417–424[Abstract/Free Full Text]
- Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J., and Ozato, K. (2004) Mol. Cell 13, 33–43[CrossRef][Medline]
[Order article via Infotrieve]
- Pivot-Pajot, C., Caron, C., Govin, J., Vion, A., Rousseaux, S., and Khochbin, S. (2003) Mol. Cell. Biol. 23, 5354–5365[Abstract/Free Full Text]
- Dey, A., Ellenberg, J., Farina, A., Coleman, A. E., Maruyama, T., Sciortino, S., Lippincott-Schwartz, J., and Ozato, K. (2000) Mol. Cell. Biol. 20, 6537–6549[Abstract/Free Full Text]
- Dey, A., Chitsaz, F., Abbasi, A., Miteli, T., and Ozato, K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 8758–8763[Abstract/Free Full Text]
- Shang, E., Salazar, G., Crowley, T. E., Wang, X., Lopez, R. A., Wang, X., and Wolgemuth, D. J. (2004) Gene Expr. Patterns 4, 513–519[CrossRef][Medline]
[Order article via Infotrieve]
- Paillisson, A., Levasseur, A., Gouret, P., Callebaut, I., Bontoux, M., Pontarotti, P., and Monget, P. (2007) Genomics 89, 215–223[CrossRef][Medline]
[Order article via Infotrieve]
- Kasahara, M. (1999) Immunogenetics 50, 134–145[CrossRef][Medline]
[Order article via Infotrieve]
- Houzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., and Beddington, R. S. P. (2002) Mol. Cell. Biol. 22, 3794–3802[Abstract/Free Full Text]
- Abbate, E. A., Voitenleitner, C., and Botchan, M. R. (2006) Mol. Cell 24, 877–889[CrossRef][Medline]
[Order article via Infotrieve]
- French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Perez-Atayde, A. R., and Fletcher, J. A. (2003) Cancer Res. 63, 304–307[Abstract/Free Full Text]
- Nakamura, Y., Umehara, T., Nakano, K., Jang, M. K., Shirouzu, M., Morita, S., Uda-Tochio, H., Hamana, H., Terada, T., Adachi, N., Matsumoto, T., Tanaka, A., Horikoshi, M., Ozato, K., Padmanabhan, B., and Yokoyama, S. (2007) J. Biol. Chem. 282, 4193–4201[Abstract/Free Full Text]
- Matangkasombut, O., and Buratowski, S. (2003) Mol. Cell 11, 353–363[CrossRef][Medline]
[Order article via Infotrieve]
- Ladurner, A. G., Inouye, C., Jain, R., and Tjian, R. (2003) Mol. Cell 11, 365–376[CrossRef][Medline]
[Order article via Infotrieve]
- Wu, S.-Y., Lee, A-Y., Hou, S. Y., Kemper, J. K., Erdjument-Bromage, H., Tempst, P., and Chiang, C.-M. (2006) Genes Dev. 20, 2383–2396[Abstract/Free Full Text]
- Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., and Ozato, K. (2005) Mol. Cell 19, 523–534[CrossRef][Medline]
[Order article via Infotrieve]
- Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., and Zhou, Q. (2005) Mol. Cell 19, 535–545[CrossRef][Medline]
[Order article via Infotrieve]
- Maruyama, T., Farina, A., Dey, A., Cheong, J., Bermudez, V. P., Tamura, T., Sciortino, S., Shuman, J., Hurwitz, J., and Ozato, K. (2002) Mol. Cell. Biol. 22, 6509–6520[Abstract/Free Full Text]
- Farina, A., Hattori, M., Qin, J., Nakatani, Y., Minato, N., and Ozato, K. (2004) Mol. Cell. Biol. 24, 9059–9069[Abstract/Free Full Text]
- You, J., Srinivasan, V., Denis, G. V., Harrington, W. J., Jr., Ballestas, M. E., Kaye, K. M., and Howley, P. M. (2006) J. Virol. 80, 8909–8919[Abstract/Free Full Text]
- Ottinger, M., Christalla, T., Nathan, K., Brinkmann, M. M., Viejo-Borbolla, A., and Schulz, T. F. (2006) J. Virol. 80, 10772–10786[Abstract/Free Full Text]
- Matangkasombut, O., Buratowski, R. M., Swilling, N. W., and Buratowski, S. (2000) Genes Dev. 14, 951–962[Abstract/Free Full Text]
- Chua, P., and Roeder, G. S. (1995) Mol. Cell. Biol. 15, 3685–3696[Abstract]
- Muchardt, C., Reyes, J.-C., Bourachot, B., Leguoy, E., and Yaniv, M. (1996) EMBO J. 15, 3394–3402[Medline]
[Order article via Infotrieve]
- Nishiyama, A., Dey, A., Miyazaki, J., and Ozato, K. (2006) Mol. Biol. Cell 17, 814–823[Abstract/Free Full Text]
- Haruki, N., Kawaguchi, K. S., Eichenberger, S., Massion, P. P., Gonzalez, A., Gazdar, A. F., Minna, J. D., Carbone, D. P., and Dang, T. P. (2005) J. Med. Genet. 42, 558–564[Abstract/Free Full Text]
- Jiang, Y. W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway, J. W., Conaway, R. C., and Kornberg, R. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8538–8543[Abstract/Free Full Text]
- Wu, S.-Y., Zhou, T., and Chiang, C.-M. (2003) Mol. Cell. Biol. 23, 6229–6242[Abstract/Free Full Text]
- Wu, S.-Y., Kershnar, E., and Chiang, C.-M. (1998) EMBO J. 17, 4478–4490[CrossRef][Medline]
[Order article via Infotrieve]
- Sanders, S. L., Jennings, J., Canutescu, A., Link, A. J., and Weil, P. A. (2002) Mol. Cell. Biol. 22, 4723–4738[Abstract/Free Full Text]
- You, J., Croyle, J. L., Nishimura, A., Ozato, K., and Howley, P. M. (2004) Cell 117, 349–360[CrossRef][Medline]
[Order article via Infotrieve]
- Phair, R. D., Scaffidi, P., Elbi, C., Vecerova, J., Dey, A., Ozato, K., Brown, D. T., Hager, G., Bustin, M., and Misteli, T. (2004) Mol. Cell. Biol. 24, 6393–6402[Abstract/Free Full Text]
- Hou, S. Y., Wu, S.-Y., Zhou, T., Thomas, M. C., and Chiang, C.-M. (2000) Mol. Cell. Biol. 20, 113–125[Abstract/Free Full Text]
- Hou, S. Y., Wu, S.-Y., and Chiang, C.-M. (2002) J. Biol. Chem. 277, 45619–45629[Abstract/Free Full Text]
- Wu, S.-Y., and Chiang, C.-M. (2001) J. Biol. Chem. 276, 34235–34243[Abstract/Free Full Text]
- Thomas, M. C., and Chiang, C.-M. (2006) Crit. Rev. Biochem. Mol. Biol. 41, 105–178[CrossRef][Medline]
[Order article via Infotrieve]
- Thomas, M. C., and Chiang, C.-M. (2005) Mol. Cell 17, 251–264[CrossRef][Medline]
[Order article via Infotrieve]
- Ilves, I., Maemets, K., Silla, T., Janikson, K., and Ustav, M. (2006) J. Virol. 80, 3660–3665[Abstract/Free Full Text]
- Schweiger, M. R., You, J., and Howley, P. M. (2006) J. Virol. 80, 4276–4285[Abstract/Free Full Text]
- McPhillips, M. G., Oliveira, J. G., Spindler, J. E., Mitra, R., and McBride, A. A. (2006) J. Virol. 80, 9530–9543[Abstract/Free Full Text]
- Oliveira, J. G., Colf, L. A., and McBride, A. A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 1047–1052[Abstract/Free Full Text]
- Dao, L. D., Duffy, A., Van Tine, B. A., Wu, S.-Y., Chiang, C.-M., Broker, T. R., and Chow, L. T. (2006) J. Virol. 80, 4792–4800[Abstract/Free Full Text]
- Kurg, R., Tekkel, H., Abroi, A., and Ustav, M. (2006) J. Virol. 80, 11218–11225[Abstract/Free Full Text]
- Van Tine, B. A., Dao, L. D., Wu, S.-Y., Sonbuchner, T. M., Lin, B. Y., Zou, N., Chiang, C.-M., Broker, T. R., and Chow, L. T. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 4030–4035[Abstract/Free Full Text]
- Parish, J. L., Bean, A. M., Park, R. B., and Androphy, E. J. (2006) Mol. Cell 24, 867–876[CrossRef][Medline]
[Order article via Infotrieve]
- Potts, P. R., Porteus, M. H., and Yu, H. (2006) EMBO J. 25, 3377–3388[CrossRef][Medline]
[Order article via Infotrieve]
- Parish, J. L., Rosa, J., Wang, X., Lahti, J. M., Doxsey, S. J., and Androphy, E. J. (2006) J. Cell Sci. 119, 4857–4865[Abstract/Free Full Text]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Cardenas-Mora, J. E. Spindler, M. K. Jang, and A. A. McBride
Dimerization of the Papillomavirus E2 Protein Is Required for Efficient Mitotic Chromosome Association and Brd4 Binding
J. Virol.,
August 1, 2008;
82(15):
7298 - 7305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Garcia-Dominguez, R. March-Diaz, and J. C. Reyes
The PHD Domain of Plant PIAS Proteins Mediates Sumoylation of Bromodomain GTE Proteins
J. Biol. Chem.,
August 1, 2008;
283(31):
21469 - 21477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. S. Crawford, J. Alsarraj, L. Lukes, R. C. Walker, J. S. Officewala, H. H. Yang, M. P. Lee, K. Ozato, and K. W. Hunter
Bromodomain 4 activation predicts breast cancer survival
PNAS,
April 29, 2008;
105(17):
6380 - 6385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mochizuki, A. Nishiyama, M. K. Jang, A. Dey, A. Ghosh, T. Tamura, H. Natsume, H. Yao, and K. Ozato
The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase
J. Biol. Chem.,
April 4, 2008;
283(14):
9040 - 9048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kapasi and D. H. Spector
Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome
J. Virol.,
January 1, 2008;
82(1):
394 - 407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Bisgrove, T. Mahmoudi, P. Henklein, and E. Verdin
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
PNAS,
August 21, 2007;
104(34):
13690 - 13695.
[Abstract]
[Full Text]
[PDF]
|
|
|
TOP
ABSTRACT
Brd4 and BET Family...